Asset profile
AZD6234
Peptide
Evidence outlook · registrational
Obesity: registrational readout pending
Entered Phase 3 on partial signal mid-stage evidence. Registrational readout expected around 2028-08-08.
ASCEND (NCT06862791): Randomized, quadruple-blind, placebo-controlled Phase 2 ASCEND trial in 377 participants with obesity or overweight, evaluating AZD6234 alone and in combination with AZD9550 against placebo; primary endpoint Percent change in body weight from baseline after 36 weeks of treatment. Completed May 2026; numerical results not yet posted to the registry, so the grade is the design ceiling for a completed controlled study without results.
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. Pick an indication; Research unlocks the trials, endpoints, key results and grades.
Competitive landscape
71 competitors in this universe: 11 direct rivals (same mechanism and indication), 0 same-class, 60 same-indication; 8 further along in development.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials |
|---|---|---|---|---|---|
| AZD6234: this drug | Phase 3 | Peptide | Amylin receptor | ||
| Amycretin | Phase 3 | Peptide | GLP-1 receptor, Amylin receptor | ||
| Cagrilintide | Phase 3 | Peptide | Amylin receptor, Amylin/calcitonin receptor (dual) | ||
| Cagrilintide / Semaglutide (CagriSema) | Phase 3 | Peptide | Amylin receptor, GLP-1 receptor | ||
| Eloralintide | Phase 3 | Peptide | Amylin receptor | ||
| MET-097i | Phase 3 | Peptide | Amylin receptor, GLP-1 receptor | ||
| Petrelintide | Phase 3 | Peptide | Amylin receptor, Amylin/calcitonin receptor (dual) | ||
| ABBV-295 | Phase 2 | Peptide | Amylin receptor | ||
| GUB-UCN2 | Phase 1/2 | Peptide | Amylin receptor | ||
| MET-233i | Phase 1/2 | Peptide | Amylin receptor | ||
| RM-718 | Phase 1/2 | Peptide | Amylin receptor | ||
| GUB014295 | Phase 1 | Peptide | Amylin receptor | ||
| Liraglutide (Saxenda / Victoza) | Approved | Peptide | GLP-1 receptor | ||
| Naltrexone / Bupropion (Contrave) | Approved | Small molecule | Opioid receptor / dopamine (combination) | ||
| Orforglipron (Foundayo) | Approved | Small molecule | GLP-1 receptor | ||
| Orlistat (Xenical / Alli) | Approved | Small molecule | Pancreatic/gastric lipase |
…and 56 more. Research shows the complete landscape.
Unlock the full comparison
Research adds each competitor's evidence grade and sourced trial results, aligned per race, so you can see who actually has the data.
Compare head-to-head
5 further head-to-head pairs are tracked; the rosters on each shared mechanism and indication page list every rival in the race.
Upcoming events
(7 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
2026 (1)
October 2026 (1)
What to watch
2027 (3)
January 2027 (1)
What to watch
February 2027 (1)
What to watch
July 2027 (1)
What to watch
2028 (3)
August 2028 (3)
All registered studies
Every ClinicalTrials.gov study of this drug's own program, grouped by indication and phase. Research unlocks the studies themselves: titles, statuses, dates and featured-trial cross-links.